Aging and remodeling of the ras and raas and related pathways: Implications for heart failure therapy

Aging and Heart Failure: Mechanisms and Management

Volumn , Issue , 2014, Pages 259-289

  Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929383051     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-0268-2     Document Type: Chapter

References (268)

1. Jugdutt BI. Prevention of heart failure in the elderly: when, where and how to begin. Heart Fail Rev. 2012. 15:531-44.
2. Weisfeldt ML. Left ventricular function. In: Weisfeldt ML, editor. The aging heart: its function and response to stress. New York: Raven. 1980. p. 297-316.
3. Lakatta EG, Gerstenblith G, Weisfeldt ML. The aging heart: structure, function, and disease. In: Braunwald E, editor. Heart disease. Philadelphia, PA: Saunders. 1997. p. 1687-700.
4. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I. Aging arteries: a “set up” for vascular disease. Circulation. 2003. 107:139-46.
5. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II. Circulation. 2003. 107:346-54.
6. Jugdutt BI. Aging and remodeling during healing of the wounded heart: current therapies and novel drug targets. Curr Drug Targets. 2008. 9:325-44.
7. Bujak M, Kweon HJ, Chatila K, et al. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J Am Col! Cardiol. 2008. 51:1384-92.
8. Jugdutt BI, Jelani A. Aging and defective healing, adverse remodeling and blunted postconditioning in the reperfused wounded heart. J Am Coll Cardiol. 2008. 51:1399-403.
9. Jugdutt BI, Jelani A, Palaniyappan A, et al. Aging- related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model. Effect of early therapy with an angiotensin II type 1 receptor blocker. Circulation. 2010. 122:341-51.
10. Jelani A, Jugdutt BI. STEMI and heart failure in the elderly: role of adverse remodeling. Heart Fail Rev. 2010. 15:513-21.
11. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010. 121:e46-215.
12. Centers for Disease Control and Prevention. Public health and aging: trends in aging: United States and worldwide. MMRW Morb Mortal Wkly Rep. 2003. 52:101-6. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5206a2.htm. Accessed 18 Aug 2011.
13. World Health Organization (WHO). Definition of an older or elderly person. http://www.who.int/health- info/survey/ageingdefnolder/en/print.html. Accessed 30 Dec 2009.
14. Jugdutt BI. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev. 2010. 15:401-5.
15. Roebuck J. When does old age begin? The evolution of the English definition. J Soc Hist. 1979. 12:416-28.
16. Holborn, H. A history of modern Germany - 18401945. Princeton University Press. 1969. p. 291-3.
17. Jugdutt BI. Heart failure in the elderly: advances and challenges. Expert Rev Cardiovasc Ther. 2010. 8: 695-715.
18. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation. 2005. 112:e154-235.
19. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009. 119:1977-2016.
20. Johansen H, Strauss B, Arnold MO, Moe G, Liu P. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol. 2003. 19:430-5.
21. Arnold MO, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and treatment. Can J Cardiol. 2006. 22:23-45.
22. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur J Heart Fail. 2008. 10:933-89.
23. McMurray J, Adamopoulos S, Anker S, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 - the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012. 14:803-69.
24. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Am Coll Cardiol. 2011. 57:2037-114.
25. Jugdutt BI. Optimal medical therapy for optimal healing. In: Lewis BS, Flugelman MY, Halon DA, editors. Proceedings 9th International Congress on Coronary Artery disease. Coronary artery diseases 2011 update- from Prevention to Intervention, Venice 2011. Bologna, Italy: Medimond. 2011. p. 243-7.
26. Jugdutt BI, Jelani A. Aging and markers of adverse remodeling after myocardial infarction. In: Jugdutt BI, Dhalla NS, editors. Cardiac remodeling.Molecular mechanisms. New York: Springer. 2013. p. 487-512.
27. Jugdutt BI. Aging and remodeling of the renin- angiotensin-system post infarction. In: Kimchi A, editor. Proceedings 15th World congress on Heart Disease, Vancouver 2010. Bologna, Italy: Medimond. 2010. p. 87-91.
28. Alexander KP, Newby LK, Armstrong PW, et al. American Heart Association Council on Clinical Cardiology. Society of Geriatric Cardiology. Acute coronary care in the elderly, Part II. ST-segment- elevation myocardial infarction. A scientific statement for healthcare professionals from the American Heart Association Council for Clinical Cardiology. Circulation. 2007. 115:2570-89.
29. Jugdutt BI. Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag. 2006. 2:125-38.
30. Heymes C, Silvestre JS, Llorens-Cortes C, et al. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology. 1998. 139:2579-87.
31. Cao XJ, Li YF. Alteration of messenger RNA and protein levels of cardiac alpha(1)-adrenergic receptor and angiotensin II receptor subtypes during aging in rats. Can J Cardiol. 2009. 25:415-20.
32. De Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol. 2009. 296:H550-8.
33. Benigni A, Corna D, Zoja C, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009. 119:524-30.
34. Fleg JL, Lakatta EG. Normal aging of the cardiovascular system. In: Aronow WS, Fleg JL, Rich MW, editors. Cardiovascular disease in the elderly. 4th ed. New York, NY: Informa. 2008. p. 1-43.
35. McCullough PA, Khandelwal AK, McKinnon JE, et al. Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. Congest Heart Fail. 2005. 11:6-11.
36. McDonald K. Diastolic heart failure in the elderly: underlying mechanisms and clinical relevance. Int J Cardiol. 2008. 125:197-202.
37. Jugdutt BI. Extracellular matrix and cardiac remodeling. In: Villarreal FJ, editor. Interstitial fibrosis in heart failure. New York, NY: Springer. 2004. p. 23-55.
38. Jugdutt BI. Regulation of fibrosis after myocardial infarction: implications for ventricular remodeling. In: Jugdutt BI, Dhalla NS, editors. Cardiac remodeling. Molecular mechanisms. New York, NY: Springer. 2013. p. 525-45.
39. Jugdutt BI. Angiotensin II, receptor blockers. In: Crawford MH, editor. Cardiology clinics annual of drug therapy, vol. 2. Philadelphia, PA: W.B. Saunders. 1998. p. 1-17.
40. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993. 153:937-42.
41. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001. 37:1047-52.
42. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-angiotensin system. Clin Sci (Lond). 2012. 123:273-84.
43. de Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol. 1998. 82:257-71.
44. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res. 2001. 88:654-8.
45. Drexler H. Endothelial dysfunction in heart failure and potential for reversal by ACE inhibition. Br Heart J. 1994. 72(3 Suppl):S11-4.
46. Seyedi N, Xu X, Nasjletti A, et al. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995. 26: 164-70.
47. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997. 99:1926-35.
48. Liu YH, Yang XP, Shesely EG, Sankey SS, Carretero OA. Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol. 2004. 43:1473-80.
49. Messadi-Laribi E, Griol-Charhbill V, Pizard A, et al. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther. 2007. 323:210-6.
50. Xu Y, Menon V, Jugdutt BI. Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCe proteins. J Renin Angiotensin Aldosterone Syst. 2000. 1:184-95.
51. Jugdutt BI, Balghith M. Enhanced regional AT2-receptor and PKCe expression during cardioprotection induced by AT1-receptor blockade after reperfused myocardial infarction. J Renin Angiotensin Aldosterone Syst. 2001. 2:134-40.
52. Jugdutt BI, Menon V. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem. 2004. 260:111-8.
53. Jugdutt BI, Menon V. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upreg- ulation in dog and rat in vivo models of reperfused myocardial infarction. J Cardiac Fail. 2004. 10:74-82.
54. Rhaleb N-E, Yang X-P, Carretero OA. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr Physiol. 2011. 1:971-93.
55. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chy- mase as the major angiotensin Il-forming enzyme in the human heart. J Biol Chem. 1990. 265:22348-57.
56. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin Il-forming pathways in normal and failing human hearts. Circ Res. 1990. 66:883-90.
57. Kawamura M, Imanashi M, Matsushima Y, et al. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol. 1992. 19:547-53.
58. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE- mediated formation of angiotensin II in chronic heart failure. Circulation. 2000. 101:844-6.
59. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997. 80: 219-27.
60. Azizi M, Menard J. Combined blockade of the renin- angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004. 109:2492-9.
61. Spinale FG, de Gasparo M, Whitebread S, et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Circulation. 1997. 96:2385-96.
62. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999. 99:990-2.
63. Yu CM, Tipoe GL, Wing-Hon Lai K, et al. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol. 2001. 38:1207-15.
64. Forteza R, Lauredo I, Abraham WM, Conner GE. Bronchial tissue kallikrein activity is regulated by hyaluronic acid binding. Am J Respir Cell Mol Biol. 1999. 21:666-74.
65. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002. 195:375-81.
66. Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003. 107:2555-8.
67. Jin D, Takai S, Sakaguchi M, Okamoto Y, Muramatsu M, Miyazaki M. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther. 2004. 309:490-7.
68. Jin D, Takai S, Yamada M, et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003. 60:413-20.
69. Matsumoto C, Hayashi T, Kitada K, et al. Chymase plays an important role in left ventricular remodeling influenced by intermittent hypoxia in mice. Hypertension. 2009. 54:164-71.
70. Oyamada S, Bianchi C, Takai S, Chu LM, Selke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther. 2011. 339:143-51.
71. Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010. 120:1229-39.
72. Pat B, Chen Y, Killingsworth C, Gladden JD, et al. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation. 2011. 122:1488-95.
73. Okumura K, Takai S, Muramatsu M, et al. Human chymase degrades human fibronectin. Clin Chim Acta. 2004. 347:223-5.
74. Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol. 2003. 41 Suppl 1:S11-8.
75. Ihara M, Urata H, Shirai K, et al. High cardiac angiotensin-II-forming activity in infarcted and non- infarcted human myocardium. Cardiology. 2000. 94: 247-53.
76. Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999. 33: 1399-405.
77. Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension. 2000. 36:638-41.
78. Uehara Y, Urata H, Sasaguri M, et al. Increased chy- mase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension. 2000. 35:55-60.
79. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res. 2002. 55:870-6.
80. Koka V, Wang W, Huang XR, et al. Advanced glyca- tion end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation. 2006. 113:1353-60.
81. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol. 2008. 294:H1675-84.
82. New RB, Sampson AC, King MK, et al. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance. Circulation. 2000. 102:1447-53.
83. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin- angiotensin-aldosterone system. Cardiovasc Res. 1999. 43:300-7.
84. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000. 102:2434-40.
85. Teerlink JR. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep. 2005. 2:191-7.
86. Schirger JA, Chen HH, Jougasaki M, et al. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin- angiotensin system and sustained sodium retention. Circulation. 2004. 109:249-54.
87. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004. 364:347-54.
88. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000. 102:1718-23.
89. Jiang BH, Tardif J-C, Shi Y, Dupuis J. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J. 2011. 37:578-86.
90. Fang JC, DeMarco T, Givertz MM, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult - a summary statement from the Pulmonary Hypertension Council of the International Society for heart and Lung Transplantation. J Heart Lung Transplant. 2012. 31:913-33.
91. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril- insensitive carboxypeptidase. J Biol Chem. 2000. 275:33238-43.
92. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000. 87:E1-9.
93. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 as an essential regulator of heart function. Nature. 2002. 417:822-8.
94. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensinconverting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol. 2005. 289:H2281-90.
95. Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol. 2005. 289:H2356-63.
96. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005. 111:2605-10.
97. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004. 43:970-6.
98. Loot AE, Roks AJ, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002. 105:1548-50.
99. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006. 48:572-8.
100. Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profiling-1 expression. Regul Pept. 2011. 166:90-7.
101. Jugdutt B, Palaniyappan A, Idikio H. Role of ACE2 and Ang (1-7) in limiting fibrosis and remodeling during healing after reperfused myocardial infarction. J Mol Cell Cardiol. 2009. 57:S24 (Abstract).
102. Cowling RT, Goldberg BH. The ACE2/Ang-(1-7) pathway in cardiac fibroblasts as a potential target for cardiac remodeling. In: Jugdutt BI, Dhalla NS, editors. Cardiac remodeling. Molecular mechanisms. New York, NY: Springer. 2013. p. 547-57.
103. Wang W, Bodiga S, Das SK, et al. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev. 2012. 17:683-9.
104. Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003. 108:1707-12.
105. Zhao YX, Yin HQ, Yu QT, et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010. 21:1545-54.
106. Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009. 15:565-71.
107. Wang Y, Moreira Mda C, Heringer-Walther S, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas’ disease and equally potent as BNP. J Card Fail. 2010. 16:157-63.
108. Xie X, Chen J, Wang X, et al. Age- and gender- related difference of ACE2 expression in a rat lung. Life Sci. 2006. 78:2166-71.
109. Yousif MH, Kehinde EO, Benter IF. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacol Res. 2007. 56:209-16.
110. Palaniyappan A, Idikio H, Jugdutt BI. Effect of age on expression of AT1 and AT2 receptors and ACE-2 and Angiotensin (1-7), Ac-SDKP and Smad-2 proteins after acute reperfused ST-segment myocardial infarction. Circulation. 2008. 118 Suppl 2:S547 (Abstract).
111. Tom B, de Vries R, Saxena PR, et al. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension. 2001. 38:95-9.
112. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005. 111:315-20.
113. Nagata S, Kato J, Sasaki K, et al. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun. 2006. 350:1026-31.
114. Jessup JA, Trask AJ, Chappell MC, et al. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normoten- sive rats. Am J Physiol. 2008. 294:H2614-8.
115. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol. 2008. 294:H2242-7.
116. Ferrario C, Varagic J, Hanini J, et al. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol. 2009. 296:H1184-92.
117. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res. 2009. 82:40-50.
118. Ahmad S, Simmons T, Varagic J, et al. Chymase- dependent generation of angiotensin II from angio- tensin-(1-12) in human atrial tissue. PLoS One. 2011. 6:e28501.
119. Ahmad S, Wei CC, Tallaj J, et al. Chymase mediates angiotensin-(1-12) metabolism in human hearts. J Am Soc Hypertens. 2013. 7:128-36.
120. Moniwa N, Wei C-C, dell’Italia LJ, et al. Chymase- mediated angiotensin II generation from angioten- sin-(1-12) in left ventricular tissue of normal and diseased human subjects. J Clin Hypertens (Greenwich). 2012. 14 Suppl 1:149 (Abstract).
121. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987. 316:1429-35.
122. Giles TD, Katz R, Sullivan JM, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989. 13:1240-7.
123. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991. 325:293-302.
124. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992. 327:685-91.
125. Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000. 21:1967-78.
126. Cleland JG, Tendera M, Adamus J, The PEPCHF Investigators, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006. 27:2338-45.
127. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997. 349:747-52.
128. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999. 100:1056-64.
129. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000. 355:1582-7.
130. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001. 345:1667-75.
131. Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003. 362:759-66.
132. McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003. 362:767-71.
133. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesar- tan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM- Alternative trial. Lancet. 2003. 362:772-6.
134. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesar- tan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003. 362:777-81.
135. White HD, Aylward PE, Huang Z, et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005. 112:3391-9.
136. Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008. 359:2456-67.
137. Timmermans PB, Carini DJ, Chiu AT, et al. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens. 1991. 4:275S-81.
138. Buhler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972. 287:1209-14.
139. Campbell DJ, Aggarwal A, Esler M, et al. p-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001. 358:1609-10.
140. Sharpe N. Benefit ofbeta-blockers for heart failure: proven in 1999. Lancet. 1999. 353:1988-9.
141. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997. 37:101-7.
142. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf. 2002. 25:73-6.
143. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003. 349:1893-906.
144. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003. 42:1206-52.
145. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003. 289:2560-72.
146. Rosendorff C, Black HR, Cannon CP, et al. American Heart Association Council for High Blood Pressure Research. American Heart Association Council on Clinical Cardiology. American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007. 115:2761-88.
147. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007. 28:1462-536.
148. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992. 327:669-77.
149. Fox KM, The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003. 362:782-8.
150. Pitt B, O’Neill B, Feldman R, et al. QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001. 87:1058-63.
151. Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. N Engl J Med. 2003. 362:782-8.
152. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006. 368:581-8.
153. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000. 355:253-9.
154. Yusuf S, Sleight P, Pogue J, et al. HOPE/HOPE- TOO Study Investigators. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000. 342:145-53.
155. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993. 329:1456-62.
156. Bosch J, Lonn E, Pogue J, et al. HOPE/HOPE_TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005. 112: 1339-46.
157. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007. 370: 829-40.
158. Kjeldsen SE, Lyle PA, Tershakovec AM, et al. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opin Emerg Drugs. 2005. 10:729-45.
159. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006. 114:838-54.
160. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995. 13:1343-51.
161. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996. 14:1147-51.
162. Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol. 1997. 37:253-7.
163. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002. 359:995-1003.
164. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002. 360:752-60.
165. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005. 23:2113-8.
166. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008. 358:1547-59.
167. Yusuf S, Diener HC, Sacco RL, et al. PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008. 359:1225-37.
168. Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008. 372:1174-83.
169. Verdecchia P, Sleight P, Mancia G, et al. ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009. 120: 1380-9.
170. Shivakumar K, Dostal DE, Boheler K, et al. Differential response of cardiac fibroblasts from young and senescent rats to ANG II. Am J Physiol Heart Circ Physiol. 2003. 284:H1454-9.
171. Basso N, Cini R, Pietrelli A, et al. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol. 2007. 293:H1351-8.
172. Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003. 42:1446-53.
173. St John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997. 96:3294-9.
174. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The investigators of the gruppo Italiano per lo Studio della supravvivenza nell’Infarcto Miocardico (GISSI-2). N Engl J Med. 1993. 329:1442-8.
175. Jugdutt BI. Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. Heart Fail Rev. 1996. 1:115-29.
176. Jugdutt BI. Ventricular remodeling post-infarction and the extracellular collagen matrix. When is enough enough? Circulation. 2003. 108:1395-403.
177. Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord. 2003. 3:1-30.
178. Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation. 1993. 88:2426-36.
179. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002. 106:2351-7.
180. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004. 109:1121-6.
181. Ferrari R, for the PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with peri- dopril on left ventricular remodeling and clinical outcome. Results of the randomized Perindopril and Remodeling Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med. 2006. 166:659-66.
182. Jugdutt BI, Palaniyappan A, Uwiera RRE, Idikio H. Role of healing-specific-matricellular proteins and matrix metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs. Mol Cell Biochem. 2009. 322:25-36.
183. Palaniyappan A, Idikio H, Jugdutt BI. Secretory leucocyte protease inhibitor and matricellular protein modulation of post reperfused myocardial infarction healing, fibrosis and remodeling in rat model. Effect of candesartan and omapatrilat. Circulation. 2009. 120 Suppl 2:S837 (Abstract).
184. Carey RM. Angiotensin receptors and aging. Hypertension. 2007. 50:33-4.
185. Pinaud F, Bocquet A, Dumont O, et al. Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats. Hypertension. 2007. 50:96-102.
186. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007. 49:341-6.
187. Chen W, Frangogiannis NG. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev. 2010. 15:415-22.
188. Ho D, Yan L, Iwatsubo K, Vatner DE, Varner SF. Modulation of p-adrenergic receptor signaling in heart failure and longevity: targeting adenyl cyclase type 5. Heart Fail Rev. 2010. 15:495-512.
189. Pitt B. The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Heart Fail Rev. 2012. 17:573-9.
190. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987. 1(8533):581-4.
191. Jugdutt BI. Intravenous nitroglycerin unloading in acute myocardial infarction. Am J Cardiol. 1991. 68(14):52D-63.
192. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004. 329:1248-9.
193. Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging. 2006. 23:131-55.
194. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999. 341:709-17.
195. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000. 102:2700-6.
196. Pitt B, Remme W, Zannad F, et al. Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003. 348:1309-21.
197. Pitt B, White H, Nicolau J, et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005. 46:425-31.
198. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009. 54:1674-82.
199. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011. 364:11-21.
200. Li X, Qi Y, Li Y, et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction. A metaanalysis of randomized controlled trials. Circ Heart Fail. 2013. 6:156-65.
201. Weidmann P, de Myttenaere-Bursztein S, Maxwell MK, de Lima J. Effect of aging on plasma renin and aldosterone in normal man. Kidney Int. 2008. 8:325-33.
202. Henschkowski J, Stuck AE, Frey BM, et al. Age- dependent decrease 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) activity in hypertensive patients. Am J Hypertens. 2008. 21:644-9.
203. Funder JW, Pearce P, Smith R, Smith AL. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor mediated. Science. 1988. 242: 583-5.
204. Edwards CR, Stewart PM, Burt D, et al. Localization of 11 beta-hydroxysteroid dehydrogenase-tissue specific receptor of the mineralocorticoid receptor. Lancet. 1988. 2:986-9.
205. Funder JW. Rales, ephesus and redox. J Steroid Biochem Mol Biol. 2005. 93:121-5.
206. Funder WF. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2008. 53(Pt 2): 286-90.
207. Bocchi B, Kenouch S, Lamarre-Cliche M, et al. Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. Hypertension. 2004. 43:803-8.
208. Chai W, Danser AHJ. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol. 2006. 374:153-62.
209. Krug AW, Allenhofer L, Monticone R, et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension. 2010. 55:1476-83.
210. Vasan RS, Demisse S, Kimura M, et al. Association of leucocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Circulation. 2008. 117:1138-44.
211. Benetos A, Gardner JP, Kimura M, et al. Aldosterone and telomere length in white blood cells. J Gerontol A Biol Sci Med Sci. 2005. 60:1593-6.
212. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003. 108:1831-8.
213. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004. 110:558-65.
214. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplere- none reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008. 51:432-9.
215. Yoshida C, Goda A, Naito Y, et al. Role of plasma aldosterone concentration in regression of left- ventricular mass following antihypertensive medication. J Hypertens. 2011. 29:357-63.
216. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013. 309:781-91.
217. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function with an aldosterone antagonist trial. Circ Heart Fail. 2013. 6:184-92.
218. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006. 48:239-45.
219. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008. 19:1459-62.
220. Pratt-Ubanama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007. 131:453-9.
221. Tomaschitz A, Pilz S, Ritz E, et al. Plasma aldoste rone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular (LURIC) health study. Eur Heart J. 2010. 31:1237-47.
222. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012. 33:191-202.
223. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009. 54:505-12.
224. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010. 55:813-8.
225. Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower beta-cell function. Hypertension. 2007. 25:2125-30.
226. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6- phosphate dehydrogenase activity. Nat Med. 2007. 13:189-97.
227. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 2002. 970:89-100.
228. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005. 45:773-9.
229. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010. 120:3350-64.
230. Keidar S, Gamliel-Lazarovich A, Kaplan M, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005. 97: 946-53.
231. Yamamuro M, Yoshimura M, Nakayama M, et al. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rats cardiomyocytes. Circ J. 2008. 72:1346-50.
232. Swedberg K, Zannad F, McMurray JJ, et al. EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study. J Am Coll Cardiol. 2012. 59: 1598-603.
233. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007. 49: 355-64.
234. Schupp N, Kolkhof P, Queisser N, et al. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J. 2011. 25:968-78.
235. Zhang Y-L, Zhou S-X, Lei J, Yuan G-Y, Wang J-F. Blockades of angiotensin and aldosterone reduce osteopontin expression and interstitial fibrosis infiltration in rats with myocardial infarction. Chin Med J. 2008. 121:2192-6.
236. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003. 93:69-76.
237. Messaoudi S, Milliez P, Samuel JL, Delcayre C. Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB J. 2009. 23: 2176-85.
238. Lother A, Berger S, Gilsbach R, et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011. 57:746-54.
239. Palmer BF. Managing hyperkalemia caused by inhibition of the nin-angiotensin-aldosterone system. N Engl J Med. 2004. 351:585-92.
240. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, the PEARL-HF investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011. 32:820-8.
241. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin- aldosterone system inhibitors involving 158998 patients. Eur Heart J. 2012. 33:2088-97.
242. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin- angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J. 2011. 32:2739-47.
243. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008. 51:1403-19.
244. Werner C, Poss J, Bohm M. Optimal antagonism of the renin-angiotensin-aldosterone system: do we need dual or triple therapy? Drugs. 2010. 70:1215-30.
245. Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699. A proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010. 56:831-8.
246. Fiebeler A, Nussberger J, Shagdarsuren E, et al. Aldosterone synthase inhibitor ameliorates angio- tensin-II induced organ damage. Circulation. 2005. 111:3087-94.
247. Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009. 75:936-44.
248. Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008. 29:2171-9.
249. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002. 39:E1-8.
250. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2008. 9:163-75.
251. Schmieder RE, Philipp T, Guerediaga J, et al. Longterm antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009. 119:417-25.
252. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008. 26:589-99.
253. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010. 24:600-8.
254. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertensionwith an oral renin inhibitor, aliskiren. Hypertension. 2003. 42:1137-43.
255. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and AngII antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation. 1997. 96:3072-8.
256. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007. 20:587-97.
257. Schefe JH, Neumann C, Goebel M, et al. Prorenin engages the pro(renin) receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens. 2008. 26:1787-94.
258. Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008. 52:1068-75.
259. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral renin inhibitor aliskiren in patients with symptomatic HF. Circ Heart Fail. 2008. 1:17-24.
260. Gheorghiade M, Albaghdadi M, Zannad F, et al. On behalf of the ASTRONAUT investigators and study coordinators. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled aliskiren trial on acute heart failure outcomes (ASTRONAUT). Eur J Heart Fail. 2011. 13:100-6.
261. Krum H, Massie B, Abraham WT, et al. ATMOSPHERE investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the aliskiren trial to minimize outcomes in patients with heart failure (ATMOSPHERE) study. Eur J Heart Fail. 2011. 13:107-14.
262. Solomon SD, Shin SH, Shah A, et al. Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011. 32:1227-34.
263. Rasilez® ASPIRE HIGHER Clinical Program Expands to 35,000 Patients in 14 Trials, The Largest Cardio-renal Outcomes Program Ever. Medical News Today, 20 June 2008. http://www.medicalnewstoday. com/releases/112086.php. Accessed 31 July 2013.
264. Parving HH, Persson F, Lewis JB, et al. AVOID study investigators. Aliskiren combined with losar- tan in type 2 diabetes and nephropathy. N Engl J Med. 2008. 358:2433-46.
265. Parving HH, Brenner BM, McMurray JJ, et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012. 367:2204-22.
266. Solomon SD, Skali H, Bourgoun M, et al. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) échocardiographie study. Am Heart J. 2005. 150:257-62.
267. Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejectioN fracTion. PARAMOUNT investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 doubleblind randomized clinical trial. Lancet. 2012. 380(9851):1387-95.
268. McMurray JJ, Packer M, Desai AS, et al. On behalf of the PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in patients with heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013. 15:1062-73.